See the DrugPatentWatch profile for boniva
Boniva (ibandronate sodium) is still available on the market [1].
How long has Boniva been available?
Boniva was approved by the U.S. Food and Drug Administration (FDA) in 2005 for the treatment of postmenopausal osteoporosis [2].
What is Boniva used to treat?
Boniva is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women. It helps to strengthen bones and reduce the risk of fractures [1].
How does Boniva work?
Boniva works by slowing down bone loss, a process called bone resorption. This allows bone-forming cells to work more effectively, leading to increased bone density and reduced fracture risk [3].
When does Boniva's patent expire?
Information on Boniva's patent expiry can be found on DrugPatentWatch.com [4]. Patents for brand-name drugs can be complex, and multiple patents may cover different aspects of a drug, such as its formulation, method of use, or manufacturing process.
Are there generic versions of Boniva available?
Yes, generic versions of ibandronate sodium are available, which can impact the market landscape for the branded drug [5].
What are the alternatives to Boniva for osteoporosis?
Other treatment options for osteoporosis include other bisphosphonates (like alendronate, risedronate, and zoledronic acid), denosumab, teriparatide, abaloparatide, and romosozumab [6]. The choice of treatment depends on individual patient factors and physician recommendation.